EUVIMEDEUVIMED entdecken
Crossref

LncRNA NNT-AS1/hsa-miR-485–5p/HSP90 axis in-silico and clinical prospect correlated-to histologic grades-based CRC stratification: A step toward ncRNA Precision

Nada M El-Sheikh, Ahmed I Abulsoud, Amal Fawzy, Eman F Wasfey, Nadia M Hamdy

Pathology - Research and Practice · 2023-07 · 247 · 154570

DOI: 10.1016/j.prp.2023.154570 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology - Research and Practice, 2023-07. Verfasst von Nada M El-Sheikh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biochemistry Department, Faculty of Pharmacy, Heliopolis University, El Salam City, 11785 Cairo, Egypt. Hauptthemen laut MEDLINE: RNA, Long Noncoding, NADP Transhydrogenases, MicroRNAs. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 98 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The oncogenic effects of long non-coding RNA (lncRNA) Nicotinamide Nucleotide Transhydrogenase-antisense RNA1 (NNT-AS1) role in colorectal cancer (CRC) hasn't been sufficiently inspected in relation to the Homo sapiens (hsa)-microRNA (miR)- 485-5p/ heat shock protein 90 (HSP90) axis, clinically. qRT-PCR was performed to detect lncRNA NNT-AS1 and hsa-miR-485-5p expression levels in 60 Egyptian patients' sera. HSP90 serum level was quantified using Enzyme-linked immunosorbent assay (ELISA). The relative expression level of the studied non-coding RNAs as well as the HSP90 ELISA concentration were correlated with patients clinicopathological characteristics and correlated to each other. The axis diagnostic utility in comparison with carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) tumor markers (TMs) was studied by receiver operating characteristic (ROC) curve analysis. The relative lncRNA NNT-AS1 expression level fold change 56.7 (13.5-112) and HSP90 protein ELISA level 6.68 (5.14-8.77) (ng/mL) were elevated, while, for hsa-miR-485-5p 0.0474 (0.0236-0.135) expression fold change was repressed in CRC Egyptian patients' cohort sera, being compared to 28 apparently healthy control subjects. LncRNA NNT-AS1 specificity is 96.4% and a sensitivity of 91.7%, hsa-miR-485-5p showed 96.4% specificity, 90% sensitivity, and for HSP90 89.3%, 70% specificity and sensitivity, respectively. Those specificities and sensitivities were superior to the classical CRC TMs. A significant negative correlation was found between hsa-miR-485-5p with lncRNA NNT-AS1 (r = -0.933) expression fold change or with HSP90 protein blood level (r = -0.997), but, significant positive correlation was there between lncRNA NNT-AS1 and HSP90 (r = 0.927). LncRNA NNT-AS1/hsa-miR-485-5p/HSP90 axis could be a prospect for CRC development as well as diagnosis. Being correlated and related to CRC histologic grades 1-3, therefore, lncRNA NNT-AS1/hsa-miR-485-5p/HSP90 axis (not individually) expression approved clinically and in silico, could aid treatment precision.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Long NoncodingNADP TranshydrogenasesMicroRNAsHumansCell ProliferationGene Expression Regulation, NeoplasticCell Line, TumorRNA, Bacterial

Stichwörter der Autor:innen

Colorectal cancerHSP90Hsa-miR-485–5pLncRNA NNT-AS1Prognositic molecular biomarkersin silico

Substanzen

RNA, Long NoncodingNADP TranshydrogenasesMicroRNAsMIRN485 microRNA, humanRNA IRNA, Bacterial

Autor:innen und Institutionen

  • Biochemistry Department, Faculty of Pharmacy, Heliopolis University, El Salam City, 11785 Cairo, Egypt.
  • Biochemistry Department, Faculty of Pharmacy, Heliopolis University, El Salam City, 11785 Cairo, Egypt; Biochemistry Department, Faculty of Pharmacy (Boy's Branch), Al-Azhar University, Nasr City, 11884 Cairo, Egypt.
  • Department of Clinical and Chemical Pathology, National Cancer Institute, Cairo University, 11796 Cairo, Egypt.
  • Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Abassia, 11566 Cairo, Egypt.
  • Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Abassia, 11566 Cairo, Egypt. Electronic address: nadia_hamdy@pharma.asu.edu.eg.

Zitieren

APA

El-Sheikh, N. M., Abulsoud, A. I., Fawzy, A., Wasfey, E. F., & Hamdy, N. M. (2023). LncRNA NNT-AS1/hsa-miR-485–5p/HSP90 axis in-silico and clinical prospect correlated-to histologic grades-based CRC stratification: A step toward ncRNA Precision. Pathology - Research and Practice, 247, 154570. https://doi.org/10.1016/j.prp.2023.154570

Vancouver

El-Sheikh NM, Abulsoud AI, Fawzy A, Wasfey EF, Hamdy NM. LncRNA NNT-AS1/hsa-miR-485–5p/HSP90 axis in-silico and clinical prospect correlated-to histologic grades-based CRC stratification: A step toward ncRNA Precision. Pathology - Research and Practice. 2023;247:154570. doi:10.1016/j.prp.2023.154570

BibTeX
@article{ElSheikh2023,
  author = {El-Sheikh, Nada M and Abulsoud, Ahmed I and Fawzy, Amal and Wasfey, Eman F and Hamdy, Nadia M},
  title = {LncRNA NNT-AS1/hsa-miR-485–5p/HSP90 axis in-silico and clinical prospect correlated-to histologic grades-based CRC stratification: A step toward ncRNA Precision},
  journal = {Pathology - Research and Practice},
  year = {2023},
  volume = {247},
  pages = {154570},
  doi = {10.1016/j.prp.2023.154570}
}
Kostenlos starten →